How do vaccine effectiveness estimates for this season’s flu vaccine compare to previous years in the UK?
This fact-check may be outdated. Consider refreshing it to get the most current information.
Executive summary
This season’s early UK data show the 2025/26 vaccine is providing strong protection in children (estimated 70–75% effective at preventing hospital attendance for ages 2–17) and more modest protection in adults (about 30–40%), which UKHSA and government releases describe as “similar to typical” seasons where effectiveness often ranges 30–60% overall [1]. UKHSA stresses vaccines still reduce severe disease despite a drifted A(H3N2) subclade driving an unusually early season; the agency is publishing ongoing, “early” effectiveness estimates while surveillance continues [2] [3].
1. Early-season headline numbers — children strong, adults moderate
Public-health summaries and press releases cite a UKHSA pre-print showing vaccine effectiveness this season at about 70–75% at preventing hospital attendance in children aged 2–17, and around 30–40% in adults; multiple outlets and the UKHSA say these are early-season estimates based on hospital-attendance analyses [1] [4]. UKHSA statements present these levels as “important protection” and note higher effectiveness is typically seen in younger age groups [1].
2. How that compares with “typical” seasons
Government commentary places these figures within the normal historical band: flu vaccine effectiveness “varies from season to season but is typically between 30 to 60%,” with higher figures in children — so the 70–75% for young people and 30–40% in adults are described as comparable to prior seasons rather than exceptional departures [1]. UKHSA explicitly states the observed levels are “similar to typical flu seasons” despite viral evolution [1].
3. Why the numbers are provisional and what “early” means
All cited reports call these estimates “early” and stress ongoing monitoring. The national surveillance reports used data up to week 48 (end of November) and emphasise that further monthly updates will follow — for example, a December monthly update was scheduled to include vaccinations between 1 September and 30 November [2]. UKHSA says it has “rapidly assessed” vaccine performance by studying hospital attendance, but also continues genetic and epidemiological monitoring of the drifted A(H3N2) subclade [3] [2].
4. The virus landscape driving the numbers — an H3N2 subclade
Surveillance shows the majority of characterised seasonal viruses this autumn have been A(H3N2); across recent weekly reports UKHSA/RVU genetic typing identified large numbers of H3N2 viruses (for example, 451 H3N2 out of 554 characterised between week 40 and 48) and noted a new drifted subclade (sometimes called “K strain” in public commentary) prompting concern [2]. UKHSA and GOV.UK briefings link that drift to the unusually early season but maintain vaccines are still protective against severe outcomes [3] [1].
5. Vaccine technology and programme context that affect effectiveness
Government guidance notes the 2025/26 programme uses a range of vaccines (including enhanced vaccines for older adults and egg‑free options) and that JCVI advice and choice of vaccines reflect efforts to optimise protection across age groups; prior seasons’ analyses informed selection of vaccine types and targeting [5] [6]. Officials also cite evidence that protection wanes in adults, which drove a later start for adult vaccination (beginning 1 October) so immunity is maximised during peak months [7] [8].
6. Competing interpretations and caveats from reporting
Media and UKHSA frame the adult 30–40% figure as “modest” but not unexpected; some outlets note it is too early to conclude whether reduced adult effectiveness or viral mutations are responsible for surging cases, explicitly saying causation cannot yet be assigned [9]. UKHSA counters with the public‑health view that even when strains drift, vaccines typically still protect well against severe illness — an argument used to urge uptake [3] [1].
7. What remains uncertain and what to watch next
Available sources emphasise ongoing surveillance: more precise vaccine effectiveness estimates, age‑stratified breakdowns, and hospitalisation versus infection endpoints will come in subsequent monthly updates and from the UKHSA pre-print being updated [2] [1]. Sources do not present final season‑long effectiveness figures yet; they repeatedly call current estimates “early” and note further analyses are underway [2].
Limitations: this analysis uses only the supplied UKHSA/Government and media excerpts; available sources do not mention full season‑end VE figures for 2025/26, nor do they provide a comprehensive statistical comparison with every prior season’s point estimates beyond the general “typically 30–60%” framing [1].